Moleculin Biotech CS (MBRX) Stock Price, Quote & News

Company Profile

Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to...

Industry: Biotechnology

Sector: Healthcare

Phone: 713 300 5160

Website: moleculin.com

Address:

5300 Memorial Drive, Suite 950, Houston, United States

LIT_L7 Jul. 2 at 12:47 PM

$MBRX W2Cap- I agree not much news until that 90th patient and an update on the 45 projected to be late 2026. Funding is the rabbit Wally has to bring out of his hat or ... I believe a majority is banking a stock sale and me too. The money needed is more than the MC so for a bp to take a position so they could buy the whole enchilada for 100 million? Maybe more maybe less but the point is they could get this drug in a phase2/3 trial that is safe and effective in a billion plus market on the cheap. Aprox. $100M sale = $17.50 a share. Annamycin is worth more than that if, and always an if with bio's, gets fda approval. Cheers-

0 · Reply

W2Cap Jul. 1 at 10:52 PM

$MBRX Yeah all fun and games but they're probably a year away from any more PR's. dead money.

0 · Reply

LIT_L7 Jul. 1 at 6:15 PM

$MBRX For only being dosed once and showing that level of response vs control arm, as the trial progresses and effect time frame is more mature, I would believe it would replicate previous study results. Great drug, great results for this patient group, all we need Wally is a sugar daddy BP to step in and partner or take over? Come on Wally, make it happen. Take one for the team. Cheers

0 · Reply

biotrade123 Jul. 1 at 5:14 PM

$MBRX I guess the brutally executed p&d of day before would've converted many short term trader to bag holders, although hopefully the long story remains

0 · Reply

ezMoney001 Jun. 30 at 10:30 PM

$MBRX Moleculin Biotech (NASDAQ: MBRX) released interim results from its Phase 2/3 MIRACLE trial for relapsed/refractory AML, where the Annamycin plus HiDAC combination demonstrated superior efficacy over HiDAC monotherapy. Data revealed first-cycle complete remission rates of 43% and 36% compared to 12% in the control arm, with composite CR rates reaching up to 57%, providing strong validation for ongoing enrollment and final dose optimization

0 · Reply

Cancercrusader Jun. 30 at 8:29 PM

$MBRX Down the toilet it goes

0 · Reply

BioBuddha Jun. 30 at 8:05 PM

$MBRX When a news is given like this which is a lie then that becomes a buy signal Here is the said news MBRX Stock Drops 25% As Moleculin Biotech's Interim Cancer Trial Data Falls Short Of Significance

0 · Reply

StocktwitsNews Jun. 30 at 6:52 PM

MBRX Stock Drops 25% As Moleculin Biotech's Interim Cancer Trial Data Falls Short Of Significance $MBRX $VXF https://stocktwits.com/news/equity/markets/mbrx-stock-drops-as-moleculin-biotech-interim-cancer-trial-data-falls-short-of-significance/cZ1QYEmR70m

0 · Reply

BG_BULL Jun. 30 at 6:22 PM

$MBRX An announcement of a good partnership will be a great end after today's trading session in which I doubled my bet 😎

0 · Reply

IVALTE Jun. 30 at 5:35 PM

$MBRX humoooooo

0 · Reply

Moleculin Biotech announces unblinded efficacy results from MIRACLE trial Part A

Jun 30, 2026, 8:30 AM EDT - 4 days ago

Moleculin Reports Positive Phase 2/3 MIRACLE Interim Results, With Annamycin Complete Remission Rates 3-fold Greater than Control

$Independent Market Research Finds Strong Physician Intent to Prescribe Moleculin's Annamycin in Relapsed/Refractory AML$

Jun 5, 2026, 8:29 AM EDT - 4 weeks ago

Independent Market Research Finds Strong Physician Intent to Prescribe Moleculin's Annamycin in Relapsed/Refractory AML

Jun 4, 2026, 8:31 AM EDT - 4 weeks ago

Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor “What This Means” Segment

May 29, 2026, 8:21 AM EDT - 5 weeks ago

Moleculin Presents ASCO 2026 Data Demonstrating No Detectable Cardiotoxicity with Annamycin Despite Exposure Levels Far Exceeding Conventional Anthracycline Limits

May 21, 2026, 5:02 PM EDT - 6 weeks ago

Moleculin Highlights Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting Highlighting Cardiac Safety Data for Annamycin

May 15, 2026, 8:30 AM EDT - 7 weeks ago

Moleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE Trial

May 14, 2026, 4:00 PM EDT - 7 weeks ago

Moleculin Biotech Quarterly report: Q1 2026

May 14, 2026, 4:00 PM EDT - 7 weeks ago

Moleculin Biotech Earnings release: Q1 2026

2026-05-13T14:09:53.000Z - 7 weeks ago

Moleculin Biotech expects first unblinding of MIRACLE trial data by June 30

May 13, 2026, 8:00 AM EDT - 7 weeks ago

Moleculin Announces Imminent MIRACLE Trial Unblinding as Blinded Data Continue to Significantly Outperform Historical Benchmarks

2026-05-12T19:17:30.000Z - 7 weeks ago

Moleculin announces publication on cardiac safety profiloe of annamycin

May 12, 2026, 9:30 AM EDT - 7 weeks ago

Independent Cleveland Clinic Review Finds No Clinically Significant Cardiotoxicity with Moleculin's Annamycin in R/R AML Patients Dosed Beyond Conventional Anthracycline Limits

2026-05-08T15:28:54.000Z - 2 months ago

Moleculin Biotech issued liposomal Annamycin patent in Hong Kong

May 8, 2026, 8:45 AM EDT - 2 months ago

Moleculin Biotech Secures Strategic Additional Patent, Strengthening Global Positioning of Annamycin

Apr 23, 2026, 8:25 AM EDT - 2 months ago

Moleculin's Annamycin Extends Survival by More Than 60% in Metastatic Pancreatic Cancer Preclinical Models - Data Presented at AACR 2026

Apr 21, 2026, 8:36 AM EDT - 2 months ago

Moleculin Announces Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting

Apr 7, 2026, 8:36 AM EDT - 3 months ago

Moleculin Releases Next CEO Corner Segment Highlighting Annamycin's Non-Cardiotoxic Profile

2026-04-02T15:10:34.000Z - 3 months ago

Moleculin Biotech management to meet with Maxim

2026-03-27T20:07:31.000Z - 3 months ago

Moleculin Biotech files to sell 6.37M shares of common stock for holders

Mar 27, 2026, 8:00 AM EDT - 3 months ago

Moleculin Biotech Registration statement: Registration filing

Mar 24, 2026, 3:00 PM EDT - 3 months ago

Moleculin Biotech Transcript: The 38th Annual Roth Conference

2026-03-23T13:23:25.000Z - 3 months ago

Moleculin Biotech announces enrollment milestone in MIRACLE trial

Mar 23, 2026, 8:31 AM EDT - 3 months ago

Moleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data Readout

2026-03-19T12:41:28.000Z - 3 months ago

Moleculin Biotech reports FY25 EPS ($28.42) vs. ($189.14) last year

2026-03-19T12:41:00.000Z - 3 months ago

Moleculin Biotech sees cash runway into 3Q26

Mar 19, 2026, 8:36 AM EDT - 3 months ago

Moleculin Reports Full Year 2025 Financial Results and Confirms Highly Anticipated 45-Patient Interim Data Unblinding in Pivotal MIRACLE Trial On Track for Mid-2026

Mar 18, 2026, 7:00 AM EDT - 3 months ago

Moleculin Biotech Earnings release: Q4 2025

Mar 18, 2026, 7:00 AM EDT - 3 months ago

Moleculin Biotech Annual report: Q4 2025

Mar 18, 2026, 7:00 AM EDT - 3 months ago

Moleculin Biotech Slides: Corporate presentation

Mar 17, 2026, 9:05 AM EDT - 3 months ago

Moleculin to Present at 38th Annual ROTH Conference

Mar 11, 2026, 9:00 AM EDT - 4 months ago

Moleculin Releases Next CEO Corner Segment Highlighting MIRACLE Study

Mar 9, 2026, 8:00 AM EDT - 4 months ago

Moleculin Biotech Proxy statement: Proxy Filing

Feb 26, 2026, 7:00 AM EST - 4 months ago

Moleculin Biotech Proxy statement: Proxy Filing

2026-02-19T13:44:53.000Z - 4 months ago

Moleculin Biotech announces exercise of warrants for $8.3M gross proceeds

Feb 19, 2026, 8:39 AM EST - 4 months ago

Moleculin Announces Exercise of Warrants for $8.3 Million Gross Proceeds

2026-02-18T13:25:45.000Z - 4 months ago

Moleculin approach first unblinding of data from Phase 2B/3 study of Annamycin

Feb 18, 2026, 8:20 AM EST - 4 months ago

Moleculin MIRACLE Trial Delivers 40% Preliminary Blinded CRc Rate (n=30)

Feb 18, 2026, 6:00 AM EST - 4 months ago

Moleculin Biotech Slides: Corporate presentation

2026-02-17T14:00:40.000Z - 4 months ago

Moleculin Biotech announces notice of allowance for JPO covering Annamycin

Feb 17, 2026, 8:35 AM EST - 4 months ago

Moleculin Announces Notice of Allowance for Japanese Patent Covering Annamycin

2026-02-13T13:35:29.000Z - 5 months ago

Moleculin Biotech announces launch of CEO Corner platform

Feb 13, 2026, 8:32 AM EST - 5 months ago

Moleculin Launches CEO Corner Platform to Share Strategic Insights

Feb 11, 2026, 1:20 PM EST - 5 months ago

Moleculin Biotech Transcript: Corporate Connect Webinar Series

Feb 5, 2026, 9:15 AM EST - 5 months ago

Moleculin to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

2026-01-13T14:01:57.000Z - 6 months ago

Moleculin Biotech reports assessment confirms no cardiotoxicity of Annamycin

Jan 13, 2026, 8:55 AM EST - 6 months ago

Moleculin Reports Independent Assessment Confirms No Cardiotoxicity of Annamycin in 90 Subjects

2026-01-12T13:46:34.000Z - 6 months ago

Moleculin Biotech says first MIRACLE trial unblinding expected in 1Q16

Jan 12, 2026, 8:36 AM EST - 6 months ago

Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs

Jan 2, 2026, 7:00 AM EST - 6 months ago

Moleculin Biotech Proxy statement: Proxy Filing

2025-12-23T21:50:21.000Z - 6 months ago

Moleculin Biotech files to sell 2.61M shares of common stock for holders

Dec 23, 2025, 7:00 AM EST - 6 months ago

Moleculin Biotech Registration statement: Registration Filing

Dec 22, 2025, 7:00 AM EST - 6 months ago

Moleculin Biotech Proxy statement: Proxy Filing

Dec 19, 2025, 7:00 AM EST - 7 months ago

Moleculin Biotech Proxy statement: Proxy Filing

2025-12-17T13:36:21.000Z - 7 months ago

Moleculin Biotech announces results from Phase 1 trial of WP1066

Dec 17, 2025, 8:31 AM EST - 7 months ago

Moleculin Announces Positive Results from Phase 1 Clinical Trial Evaluating WP1066 for the Treatment of Pediatric Recurrent Malignant Brain Tumors

2025-12-15T17:20:30.000Z - 7 months ago

Moleculin Biotech target adjusted to $31 from $300 at Roth Capital

2025-12-11T11:25:22.000Z - 7 months ago

Moleculin Biotech target adjusted to $22 from $4 at H.C. Wainwright

Dec 10, 2025, 8:30 AM EST - 7 months ago

Moleculin Announces Exercise of Warrants for $6.8 Million Gross Proceeds

2025-12-09T13:15:50.000Z - 7 months ago

Moleculin Biotech provides update on enrollment for MIRACLE study

Dec 9, 2025, 8:07 AM EST - 7 months ago

Moleculin Announces Completion of Treatment for the 45 Patients in Pivotal “MIRACLE” Phase 3 AML Trial on Pace for Q1 2026

Dec 8, 2025, 8:21 AM EST - 7 months ago

Moleculin Announces New Annamycin Collaboration in Brain Tumors

Nov 26, 2025, 9:15 AM EST - 7 months ago

Moleculin to Participate in the Virtual Investor Closing Bell Series

Nov 26, 2025, 9:00 AM EST - 7 months ago

Moleculin Announces Reverse Stock Split

Nov 13, 2025, 8:36 AM EST - 8 months ago

Moleculin Reports 60% of First 45 Subjects in Pivotal “MIRACLE” Phase 3 AML Trial Consented

Nov 13, 2025, 7:00 AM EST - 8 months ago

Moleculin Biotech Quarterly report: Q3 2025

Nov 12, 2025, 8:37 AM EST - 8 months ago

Moleculin Announces Grant Funded Research Evaluating Annamycin for the Treatment of Pancreatic Cancer at UNC-Chapel Hill

Oct 30, 2025, 8:40 AM EDT - 8 months ago

Moleculin to Highlight its Ongoing Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial at the 14th Annual Acute Leukemia Meeting

Oct 29, 2025, 8:35 AM EDT - 8 months ago

Moleculin Expands Global IP Portfolio with New Australian Patent for Annamycin

Oct 23, 2025, 8:00 AM EDT - 9 months ago

Moleculin Announces New Investigator-Initiated Study of Annamycin for Treating Pancreatic Cancer

Sep 25, 2025, 8:35 AM EDT - 10 months ago

Moleculin Announces Notice of Allowance for Canadian Patent Covering Annamycin

Sep 19, 2025, 8:00 AM EDT - 10 months ago

Moleculin Biotech Registration statement: Registration Filing

Sep 15, 2025, 8:00 AM EDT - 10 months ago

Moleculin Biotech Proxy statement: Proxy Filing

Sep 9, 2025, 8:45 AM EDT - 10 months ago

Moleculin Accelerates Recruitment in Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial

Sep 8, 2025, 8:30 AM EDT - 10 months ago

Moleculin Doses First EU Patient in Phase 3 Pivotal MIRACLE Trial for Treatment of Acute Myeloid Leukemia

Sep 5, 2025, 8:00 AM EDT - 10 months ago

Moleculin Biotech Proxy statement: Proxy Filing

Aug 28, 2025, 8:30 AM EDT - 11 months ago

Moleculin Announces Exercise of Warrants for $6.0 Million Gross Proceeds

Aug 27, 2025, 8:45 AM EDT - 11 months ago

Moleculin Issues New Positive AML Overall Survival Data:

Aug 14, 2025, 9:15 AM EDT - 11 months ago

Moleculin to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Aug 13, 2025, 8:05 AM EDT - 11 months ago

Moleculin Reports Second Quarter 2025 Financial Results and Highlights

Aug 13, 2025, 8:00 AM EDT - 11 months ago

Moleculin Biotech Earnings release: Q2 2025

Aug 13, 2025, 8:00 AM EDT - 11 months ago

Moleculin Biotech Quarterly report: Q2 2025

Aug 6, 2025, 8:40 AM EDT - 11 months ago

Moleculin Biotech, Inc. Unveils Promising Preclinical Data of Annamycin in Liver Cancer Treatment

Jul 30, 2025, 8:35 AM EDT - 1 year ago

Moleculin Receives Notice of Intent to Grant New European Patent for Annamycin

Jul 22, 2025, 8:45 AM EDT - 1 year ago

Moleculin Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Jul 17, 2025, 8:25 AM EDT - 1 year ago

Moleculin Engages Industry Veteran Adriano Treve to Explore Accelerated Strategic Partnerships

Jul 9, 2025, 8:35 AM EDT - 1 year ago

Moleculin Expands Phase 3 MIRACLE Clinical Trial into the Country of Georgia, Enrollment Update and Future Plans

Jul 8, 2025, 8:00 AM EDT - 1 year ago

Moleculin Biotech Proxy statement: Proxy Filing

Jul 8, 2025, 8:00 AM EDT - 1 year ago

Moleculin Biotech Proxy statement: Proxy Filing

Jun 27, 2025, 8:00 AM EDT - 1 year ago

Moleculin Biotech Proxy statement: Proxy Filing

Jun 20, 2025, 9:20 AM EDT - 1 year ago

Moleculin Announces $5.9 Million Public Offering

Jun 18, 2025, 7:45 AM EDT - 1 year ago

Moleculin Participates in Virtual Investor “What This Means” Segment

Jun 18, 2025, 7:30 AM EDT - 1 year ago

Moleculin Receives Positive FDA Feedback on Pediatric Study Plan for Annamycin in Children with R/R AML

Jun 16, 2025, 8:00 AM EDT - 1 year ago

Moleculin Biotech Registration statement: Registration Filing

Jun 11, 2025, 8:00 AM EDT - 1 year ago

Moleculin Biotech Registration statement: Registration Filing

Jun 6, 2025, 8:00 AM EDT - 1 year ago

Moleculin Biotech Registration statement: Registration Filing

Jun 5, 2025, 8:30 AM EDT - 1 year ago

Moleculin Biotech Transcript: Study Update

Jun 5, 2025, 8:30 AM EDT - 1 year ago

Moleculin Biotech Press release: Study Update

Jun 5, 2025, 8:00 AM EDT - 1 year ago

Moleculin Releases On-Demand KOL Webcast to Discuss Data from its Phase 1B/2 Study of Annamycin for the Treatment of Soft Tissue Sarcoma (STS) Lung Metastases (MB-107)

LIT_L7 Jul. 2 at 12:47 PM

0 · Reply

W2Cap Jul. 1 at 10:52 PM

$MBRX Yeah all fun and games but they're probably a year away from any more PR's. dead money.

0 · Reply

LIT_L7 Jul. 1 at 6:15 PM

0 · Reply

biotrade123 Jul. 1 at 5:14 PM

$MBRX I guess the brutally executed p&d of day before would've converted many short term trader to bag holders, although hopefully the long story remains

0 · Reply

ezMoney001 Jun. 30 at 10:30 PM

0 · Reply

Cancercrusader Jun. 30 at 8:29 PM

$MBRX Down the toilet it goes

0 · Reply

BioBuddha Jun. 30 at 8:05 PM

0 · Reply

StocktwitsNews Jun. 30 at 6:52 PM

0 · Reply

BG_BULL Jun. 30 at 6:22 PM

$MBRX An announcement of a good partnership will be a great end after today's trading session in which I doubled my bet 😎

0 · Reply

IVALTE Jun. 30 at 5:35 PM

$MBRX humoooooo

0 · Reply

stockmathy Jun. 30 at 2:40 PM

$MBRX at least the question is no mote about product but it is about how Wally chooses to secure his financial requirements….by burning his share holders repeatedly or get into partnerships and finally reward his shareholders and stop ripping shareholders

1 · Reply

MacroMarty Jun. 30 at 2:32 PM

$MBRX https://moleculin.com/moleculin-reports-positive-phase-2-3-miracle-interim-results-with-annamycin-complete-remission-rates-3-fold-greater-than-control/

0 · Reply

LIT_L7 Jun. 30 at 2:29 PM

$MBRX BioBuddha, I agree with you that a partnership would be a great leg up for MBRX. Looking at the companies making and marketing in this are, Pfizer, Sanofi, Roche, Teva... I belive they are watching out for all competition and MBRX has to be on their radar. Annamycin with no cardio toxicity? There's a game changer already. Bumpy ride, of course with this managements record. What ya got Wally up your sleeve? Cheers-

1 · Reply

Psid12 Jun. 30 at 2:29 PM

$MBRX I don’t understand! What was the consensus about the data good or bad why the sell off

2 · Reply

BioBuddha Jun. 30 at 2:19 PM

$MBRX buy when market is fearful. Look at rvmd - there was dilution and they kept it low for a few weeks and now it is off to races. Mbrx may dilute may partner - but this stock has turned a corner

0 · Reply

mokaz1 Jun. 30 at 2:19 PM

$MBRX lol

0 · Reply

Darkswede Jun. 30 at 2:07 PM

$MBRX WTF? Double digits? Looks like heading to a Single. This is what AI does. Garbage in, Garbage out. Show me the money..the toxic finance companies having the last laugh.

0 · Reply

Aye_Rooster Jun. 30 at 2:05 PM

$MBRX Sorry guys, i bought in yesterday. Should have wartned you.

0 · Reply

Psid12 Jun. 30 at 2:05 PM

$MBRX what is the next catalyst to come due, I hope they get some financial incentives for this data

2 · Reply

LIT_L7 Jun. 30 at 1:59 PM

$MBRX Pretty much follows prior data. This is early data results and single dose vs longer time frame and multiple doses from prior data. Closing in on the 90 patients at 67? Not bad. I am sure Wally has already checked the office couches for spare change but I am expecting an offering soon. That would be a good time to add on the fluctuation. I wonder at what price? I recommend a double shot of Maker if the pr has made you anxious and dose on the hour until all anxiety left or until you fall over. It really is a good update. Cheers-

0 · Reply

Aussietradz Jun. 30 at 1:48 PM

$MBRX what a shit show

1 · Reply

NigelOleg Jun. 30 at 1:46 PM

$MBRX $2.56 currently 😭

0 · Reply

Market Cap	14.09M
Revenue (ttm)	0.00
Net Income (ttm)	-33.56M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	361,500
Avg Vol	599,392
Day's Range	N/A - N/A
Shares Out	5.34M
Stochastic %K	22%
Beta	1.75
Analysts	Strong Sell
Price Target	$21.00